K. W. Mahaffey

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Truman J. Milling, Saskia Middeldorp, Lizhen Xu et al. · Circulation · 2023 · 152 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial

Glenn M. Chertow, R Correa-Rotter, Geoffrey A. Block et al. · Nephrology Dialysis Transplantation · 2012 · 46 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Impact of Complete Revascularization in the ISCHEMIA Trial

Gregg W. Stone, Ziad A. Ali, Sean M. O’Brien et al. · Journal of the American College of Cardiology · 2023 · 45 citations · Full text

Medicine, Cardiology, Surgery +12

Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial

Peter B. Berger, K. W. Mahaffey, Susan Meier et al. · American Heart Journal · 2002 · 42 citations

Medicine, Cardiology, Pharmacotherapy +17

Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA{middle dot}CER) trial

Sergio Leonardi, Pierluigi Tricoci, HD White et al. · European Heart Journal · 2013 · 37 citations

Medicine, Cardiology, Pharmacology +17